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Aceruloplasminemia (ACP) is a rare, adult-onset, autosomal recessive disorder,
characterized by systemic iron overload due to mutations in the Ceruloplasmin gene
(CP), which in turn lead to absence or strong reduction of CP activity. CP is a ferroxidase
that plays a key role in iron export from various cells, especially in the brain, where
it maintains the appropriate iron homeostasis with neuroprotective effects. Brain iron
accumulation makes ACP unique among systemic iron overload syndromes, e.g.,
various types of genetic hemochromatosis. The main clinical features of fully expressed
ACP include diabetes, retinopathy, liver disease, and progressive neurological symptoms
reflecting iron deposition in target organs. However, biochemical signs of the disease,
namely a mild anemia mimicking iron deficiency anemia because of microcytosis and
low transferrin saturation, but with “paradoxical” hyperferritinemia, usually precedes the
onset of clinical symptoms of many years and sometimes decades. Prompt diagnosis
and therapy are crucial to prevent neurological complications of the disease, as they are
usually irreversible once established. In this mini-review we discuss some major issues
about this rare disorder, pointing out the early clues to the right diagnosis, instrumental
to reduce significant disability burden of affected patients.
Keywords: iron metabolism, iron overload disease, neurodegeneration with brain iron accumulation, rare
anemias, Aceruloplasminemia
INTRODUCTION
With the increasing awareness of an abnormal local iron accumulation in highly impacting
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease (for review see references
Ke and Ming, 2003; Ward et al., 2014), attention in understanding the peculiarities of iron
metabolism in the brain has steadily raised (Raha et al., 2013; Rouault, 2013). CP is a copper-
containing ferroxidase enzyme that plays a key role in cellular iron export, and has been postulated
to have a neuroprotective function (Wang and Wang, 2018). In this context Aceruloplasminemia
(ACP) represents a paradigmatic disorder highlighting how the loss of CP function causes iron
accumulation and neurodegeneration.
Aceruloplasminemia is a rare, adult-onset, autosomal recessive disease caused by mutations in
the CP gene, encoding CP. The impairment of CP ferroxidase activity results in pathological cellular
iron retention and iron-mediated oxidative damage. The spectrum of clinical manifestations
includes mild microcytic anemia, diabetes mellitus, liver disease, retinopathy, and progressive
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neurodegeneration due to iron accumulation in the brain
and other parenchymal organs (Miyajima and Hosoi, 1993–
2018; Kono, 2013). ACP is variably classified into different
subgroups of rare diseases, such as neurodegeneration with brain
iron accumulation (NBIA) (Hogarth, 2015), atypical microcytic
anemias (Camaschella, 2013; Donker et al., 2014; Brissot et al.,
2018), and non-HFE iron overload syndromes (Pietrangelo et al.,
2011), depending on the specialists who see the patients for the
first time. Apart from few neurologists and hematologists, the
awareness of this disease is poor even among other specialists
that could intercept the patients at various stages of their clinical
history, such as diabetologists and ophthalmologists. Indeed, the
commonly reported consistent diagnostic delay illustrates how
ACP is under-recognized in most cases (Miyajima and Hosoi,
1993–2018; Vroegindeweij et al., 2015). This represents a major
problem, since prompt diagnosis, and treatment are crucial to
prevent neurological complications of the disease, which are
usually irreversible once established. In this mini-review we
outline some major issues about this rare disease, including
the limited knowledge about epidemiology and genotype-
phenotype correlation, as well as the challenges in diagnosis
and therapy.
EPIDEMIOLOGY
Our knowledge on the epidemiology of ACP is largely based
on studies in the Japanese population, where the disease
was first reported in 1987 by Miyajima and collaborators,
through the description of a 52-year-old woman presenting
with blepharospasm, retinal degeneration and diabetes mellitus
(Miyajima et al., 1987). The same Authors later estimated
the prevalence of the disease as being roughly 1:2,000,000 in
Japanese individuals born from non-consanguineous marriages.
Such estimation was inferred by a study in an adult population
where serum CP was systematically measured with subsequent
sequencing of the CP gene in individuals having low serum values
(Miyajima et al., 1999). This estimation has obvious regional
limitations, and cannot be applied in non-Japanese population,
where ACP prevalence is actually unknown. Few more than one
hundred of patients have been described in the literature so far,
with a worldwide geographical distribution (Miyajima and Hosoi,
1993–2018; Kono, 2013; Doyle et al., 2015; Vroegindeweij et al.,
2015; Pelucchi et al., 2018; Riboldi et al., 2018; Yamamura et al.,
2018). While Japanese patients with neurological involvement
still represent the majority (Miyajima and Hosoi, 1993–2018)
the second group is represented by Italian patients reported by
some referral centers for disorders of iron metabolism (Pelucchi
et al., 2018). Nonetheless, ACP has been described also in
other European countries (Spain, France, Netherlands, Belgium,
Poland), as well as in China and in African American patients
(Shang et al., 2006; Parks et al., 2013; Vroegindeweij et al., 2017;
Riboldi et al., 2018). The generally low disease awareness, as well
as a negative publication bias of single cases, represents possible
explanations for the limited number of reports. An effort is
needed to increase disease awareness especially among specialists
in neurology, hematology, and endocrinology, in order to reduce
the unacceptable diagnostic delay that is usually of decades after
the appearance of the first biochemical and/or clinical signs of the
disease (Miyajima and Hosoi, 1993–2018; Vroegindeweij et al.,
2015; Pelucchi et al., 2018).
PATHOPHYSIOLOGY: RECENT
ADVANCES AND UNRESOLVED ISSUES
Aceruloplasminemia is caused by biallelic mutations in the CP
gene, a 20 exons gene encompassing approximately 65 kb of
DNA, located in chromosome locus 3q24-q25 and encoding
CP (Yoshida et al., 1995; Hellman and Gitlin, 2002; Kono,
2013). CP is a single polypeptide chain of 1,046 amino acids
that can bind up to six atoms of copper. The crystallographic
3D structure of the protein shows its six structural domains
with a three-copper catalytic center that is crucial for its
oxidative function (Bento et al., 2007). Copper is incorporated
into CP before its secretion and this phase is crucial for its
function and stability (Sato and Gitlin, 1991). Indeed, secretion
of a copper-deficient CP leads to its rapid degradation in
the plasma (Hellman and Gitlin, 2002). Two distinct isoforms
of CP are produced by an alternative splicing in exons 19
and 20: a soluble form that is present in the plasma, and
a glycosylphosphatidylinositol (GPI)-anchored membrane form
(Patel et al., 2000). The soluble isoform is almost exclusively
synthetized by hepatocytes, and accounts for near 95% of copper
in the plasma (Hellman and Gitlin, 2002). On the other hand,
the GPI-anchored membrane isoform is produced and expressed
by a number of cells, including brain astrocytes glial cells,
hepatocytes, macrophages, pancreatic, and retinal epithelial cells
(Kono et al., 2010). The soluble form is involved in NO oxidation
and homeostasis (Shiva et al., 2006), while the membrane isoform
plays a key role in cellular iron egress (Muckenthaler et al.,
2017). Indeed, CP cooperates with ferroportin, the ubiquitous
and unique transmembrane protein able to export ferrous
iron (Fe2+) from the cells (Drakesmith et al., 2015). This
process needs to be completed by copper-mediated oxidation
to ferric iron (Fe3+), to ensure the appropriate binding of
extracellular iron to transferrin (Miyajima and Hosoi, 1993–
2018). GPI-anchored CP has been also reported to interfere
with the modulation of ferroportin activity by hepcidin (Nemeth
et al., 2004; Kono, 2013; Aschemeyer et al., 2018), the master
regulator of systemic iron homeostasis (Ganz, 2013). Membrane
bound CP is therefore essential for ensuring a regular iron
handling by various cells, including neurons that need iron
for synthesis of neurotransmitters, energetic metabolism, and
myelin formation (Miyajima and Hosoi, 1993–2018). According
to the current model mainly based on animal experiments
(Jeong and David, 2006), early neuronal injury in ACP may
be related to the inability to uptake iron from the CP-deficient
astrocytes. In advanced ACP, neurodegeneration may be due
to iron accumulation and ensuing oxidative damage (Miyajima
and Hosoi, 1993–2018; Kono and Miyajima, 2006; Kono, 2013),
astrocytes loss and neuronal uptake of alternative and toxic
iron sources, i.e., non-transferrin bound iron (NTBI) (Breuer
et al., 2000). A basic model of astrocyte/neuronal iron handling
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FIGURE 1 | (A) Different functions of soluble and membrane-bound ceruloplasmin. Ferroxidase activity of membrane-bound CP is essential since only Fe3+ (but not
Fe2+) can be incorporated into plasma transferrin, and then delivered to other cells (mainly erythroid precursors) via Transferrin Receptor 1 (TfR1). (B,C) Model of iron
cross-talk between astrocytes and neuronal cells. (B) Ceruloplasmin is needed to oxidize Fe2+ into Fe3+, the only iron form that can be bound to transferrin for
appropriate iron uptake by neurons through the transferrin receptor type 1 (TfR1). (C) Lack of ceruloplasmin leads to initial iron accumulation into astrocytes and
starvation of neurons, with ensuing alteration of energetic metabolism and synthesis of neurotransmitters. This later stimulates the neuronal uptake alternative
sources of iron, like non-transferrin-bound iron (NTBI), which is further toxic.
is depicted in Figure 1. Lack of CP impairs this model, and,
in general, ferroportin-mediated iron export from several cells.
While this model explains iron maldistribution in critical cell
types of ACP patients (e.g., astrocytes, neurons, hepatocytes,
pancreatic, and retinal cells), it does not explain well why total
iron stores are increased in such disease. This point needs the
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postulation of a ferroportin-mediated increase of dietary iron
absorption by intestinal cells. Intestinal ferroportin, expressed on
the basolateral membrane, works in synergy with the CP homolog
hephaestin, another multicopper oxidase that is responsible for
the transition Fe2+→Fe3+ needed for iron incorporation into
plasma transferrin (Vulpe et al., 1999; Muckenthaler et al., 2017).
Thus, this mechanism should be unaffected in ACP. Nevertheless,
increased iron absorption should imply inappropriately low levels
of hepcidin, the main negative regulator of ferroportin activity
(Drakesmith et al., 2015; Muckenthaler et al., 2017). Indeed,
low level of hepatic hepcidin expression has been reported
in an ACP mouse model (Guo et al., 2009), and few ACP
patients tested for serum hepcidin levels had levels in the lower
range (Kaneko et al., 2010). While the latter finding needs
confirmation in larger series, it remains to be explained why
lack of CP leads to hepcidin suppression, particularly in patients
with typically increased liver iron deposits that should stimulate
rather than inhibit hepcidin production (Girelli et al., 2016).
The iron-restricted erythropoiesis typically found in ACP (see
below), due to impaired iron recycling, could stimulate the
production of erythroferrone (ERFE) by bone marrow erythroid
precursors, which in turn is a potent inhibitor of hepcidin
(Kautz et al., 2014). However, up to now ERFE levels have
never been measured in ACP patients. Anyway, things are
likely more complicated than expected. For example, even if
soluble CP is not able to pass the blood-brain barrier, it is
also present in the brain through secretion by epithelial cells
of the choroid plexus into the cerebrospinal fluid (Hellman
and Gitlin, 2002). Moreover, the role of hephaestin may
not be limited to intestinal iron absorption, since HEPH-KO
mice have shown a dysregulation of brain iron homeostasis
(Jiang et al., 2015).
Overall, it emerges that CP is part of a complex regulatory
system that protects brain from either systemic iron deficiency
or oxidative damage due to iron overload. In ACP the loss of
this regulation results in neurodegeneration, as well as increased
iron stores and toxic damage localized in other organs, especially
liver, pancreas, and retina. A better understanding of the ACP
pathophysiology could result in more efficient treatments, which
for the moment are essentially limited to poorly effective iron
chelation (see below).
GENOTYPE-PHENOTYPE
CORRELATIONS
Disease-related mutations in the CP gene are usually private,
leading to absent or severely reduced ferroxidase activity of
CP. To the best of our knowledge 28 missense, 17 frameshift,
13 splicing and 8 nonsense mutations have been described
(Miyajima and Hosoi, 1993–2018; Pelucchi et al., 2018).
Missense mutations lead usually to impairment of protein
stability or alteration in copper binding domains. The majority
of cases are due to homozygous mutations (which should
prompt to ask for history of consanguinity), but compound
heterozygosity has been also described. A milder disease
course has been reported in some individuals with a single
CP mutation (simple heterozygosity) (McNeill et al., 2008b).
Possible explanations for such cases could be a second mutation
in CP non-studied regions, in other relevant genes involved in
genetic iron overload (compound heterozygosity) (Camaschella,
2005), or a dominant-negative effect of mutant CP through
silencing the wild-type CP, i.e., causing retention also of
the wild type CP in the endoplasmic reticulum (Kono,
2013). While no clear genotype-phenotype correlation is
usually reported, recent observations suggest that some CP
genotypes (i.e., homozygosity for Cys338Ser or for Ile991Thr)
could be associated to residual ferroxidase activity, resulting
in no or less frequent neurological impairment (Pelucchi
et al., 2018). On the other hand, homozygosity for the
Gly631Arg mutation has been associated in almost all
cases to extra-pyramidal symptoms in Caucasian patients
(Vroegindeweij et al., 2017).
CLINICAL FEATURES
Aceruloplasminemia is the only known iron overload disorder
in which brain and systemic iron overload are combined.
Neurodegeneration typically involves the dentate nuclei of
cerebellum, basal ganglia, and thalamus, and is detectable
by MRI showing in these regions diffuse hypointensity in
T2∗ and T2 fast spin echo (FSE) sequences (McNeill et al.,
2008a). The classical clinical triad of retinal degeneration,
dementia and diabetes is frequently cited, mainly based on
observations in Japanese patients (Miyajima et al., 2003).
The largest review of clinical manifestations was based on
71 cases, most them being Japanese (Miyajima and Hosoi,
1993–2018). However, recent non-Japanese case series have
highlighted a broader clinical and molecular heterogeneity
(Vroegindeweij et al., 2017; Pelucchi et al., 2018). According
to these descriptions, the clinical presentation of ACP usually
leading to the diagnosis by neurologists includes cerebellar
signs (dysarthria, ataxia of trunk, and limbs) and involuntary
movements (dystonia, chorea, tremors), with an onset between
40 and 60 years of age (Miyajima and Hosoi, 1993–2018).
At variance with this “typical” picture in Japanese ACP
patients, cognitive-psychiatric changes and extrapyramidal
signs are apparently more frequent in Caucasians, with a
trend toward an earlier onset (Vroegindeweij et al., 2017).
However, cognitive alterations (apathy, memory loss) and
behavioral changes have a low specificity and can be often
underestimated. When ACP is suspected on the basis of
neurological symptoms, a brain MRI with specific sequences
must be performed (McNeill et al., 2008a). In such cases,
the differential diagnosis mainly includes other NBIAs and
Wilson’s disease.
On the other hand, increasing reports point out the presence
of a mild microcytic anemia as the earliest biochemical sign of
ACP, in both Japanese and non-Japanese cases, which can be
often traceable in patient’s history since childhood (Miyajima
and Hosoi, 1993–2018; Pelucchi et al., 2018). Unfortunately,
it rarely leads to the diagnosis of ACP in the early pre-
symptomatic stage. Diabetes mellitus (DM) is another classical
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manifestation of ACP. It generally presents in the fourth to
sixth decade, often in subjects without classical risk factors
for diabetes, and requires insulin treatment (Vroegindeweij
et al., 2017). As for mild anemia, in most cases of ACP
DM is not appropriately recognized as part of a systemic
disorder. The mechanism leading to DM in ACP is poorly
understood. Of note, iron accumulation appears prevalent in
exocrine rather than endocrine pancreas cells (Kato et al.,
1997). Liver iron accumulation, reflecting systemic iron overload,
is often present in ACP but rarely leads to clinically overt
manifestations such as cirrhosis and liver failure (Miyajima and
Hosoi, 1993–2018; Pelucchi et al., 2018). When liver biopsy is
performed, iron accumulation is prevalent in hepatocytes like
in classical HFE-related hemochromatosis, which can also be
misleadingly considered in the differential diagnosis (Hellman
et al., 2000). Retinopathy is frequently reported in Japanese ACP
patients, but a uniform morphological description is lacking
and it infrequently causes clinically relevant visual impairment
(Miyajima and Hosoi, 1993–2018; He et al., 2007). In non-
Japanese case series, retinopathy is far less frequent, and its
attribution to ACP per se is often uncertain (Pelucchi et al.,
2018). Finally, iron overload in other organs, such as heart and
endocrine glands other than pancreas, has been sporadically
reported in both Caucasian and Japanese patients, but the true
prevalence may be actually under-investigated (Miyajima and
Hosoi, 1993–2018; Badat et al., 2015).
The lack of uniform description of ACP cases makes it difficult
to draw firm conclusions about the prognosis in these patients.
Nonetheless, it is clear that neurological manifestations, when
present, have the main impact on the quality of life of the patients
and their families.
A summary of ACP main clinical features is depicted
in Figure 2.
ACP DIAGNOSIS: INCREASING
DIAGNOSTIC SENSITIVITY BY USING
THE “BIOCHEMICAL” TRIAD RATHER
THAN THE “CLINICAL” TRIAD
As mentioned above, mild microcytic anemia, low transferrin
saturation (TSAT), and hyperferritinemia are the first detectable
signs of ACP according to all the major case series (Miyajima
and Hosoi, 1993–2018; Pelucchi et al., 2018). This biochemical
triad is pivotal in the definition of an “atypical microcytic
anemia,” as opposed to typical cases due to iron deficiency
in which serum ferritin levels are consistently low. Such
triad may still be due to relatively frequent conditions, i.e.,
thalassemia syndromes and the so called anemia of inflammation,
but once these hypotheses are easily discarded (i.e., by
other obvious clinical clues and/or biochemical markers of
inflammation), the differential diagnosis should consider a
definite number of rare disorders. Besides ACP, they include
ferroportin disease, congenital sideroblastic anemias, DMT1-
deficiency and atransferrinemia (for extensive reviews see
Camaschella, 2013; Donker et al., 2014; Brissot et al., 2018).
FIGURE 2 | Clinical clues for ACP diagnosis. Percentages are taken from references (Miyajima and Hosoi, 1993–2018; Vroegindeweij et al., 2017;
Pelucchi et al., 2018).
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In ACP, microcytic anemia and low TSAT are likely due to
an impairment of iron recycling leading to an iron-restricted
erythropoiesis. The resulting anemia is generally mild likely
because other oxidation systems independent from CP can
counteract the lack of this protein, allowing a certain degree
of availability of iron for erythroid precursors. Anyway, in
this condition the diagnosis of ACP long before other clinical
manifestations can be easily done by assessing serum CP levels,
which are usually undetectable or clearly below the normal
range (Kono, 2013). Low CP levels can be detected also in
asymptomatic CP heterozygotes, Wilson disease, Menkes disease
or hypoproteinemias, which can be distinguished from ACP
because of different clinical features before eventually molecular
analysis. The majority of CP pathogenic mutations produce a
dysfunctional and unstable apo- CP that is rapidly degraded
in the plasma resulting in undetectable levels by conventional
assays. However, in a minority of cases, serum CP can be
only mildly decreased or normal. In such ultra-rare cases, a
functional assay that explores the CP ferroxidase activity can
be useful (Erel, 1998). This assay has also been reported of
prognostic value, since residual ferroxidase activity has been
associated to better neurological outcome, although in few
observations (Pelucchi et al., 2018). Finally, low hepcidin levels
are usually found in ACP patients, helping in the differential
diagnosis of iron overload disorders (Kaneko et al., 2010;
Girelli et al., 2016).
TREATMENT OF ACP: STILL
UNSATISFACTORY
Up to now, our knowledge on ACP treatment is mainly
based on case reports. The most common approach is based
on iron-chelating agents. At variance with deferoxamine and
deferasirox, deferiprone is the only available iron chelator
that is able to cross the blood-brain barrier, due to its low
molecular weight and lipophilic properties (Kono, 2013). In
general, all these drugs have shown encouraging results in
reducing serum ferritin and iron accumulation in the liver
(Finkenstedt et al., 2010; Kono, 2013). However, their efficacy
on brain iron accumulation and neurological manifestations
is controversial. Some studies indicate that they may prevent
or slow down neurodegeneration, therefore early initiation
of treatment is crucial (Pelucchi et al., 2018). However, the
overall efficacy of iron chelation therapy in neurodegenerative
disorders with brain iron accumulation is difficult to assess
because of the lack of standardized description of clinical
and MRI findings in ACP patients. According to a recent
review, “there is no compelling evidence of the clinical effect of
iron removal therapy on any neurological disorder,” including
ACP (Dusek et al., 2016). Moreover poor tolerance to iron
chelators, even including worsening of anemia due to further
iron subtraction for erythropoiesis, has been often reported,
limiting the long-term use of such agents that would be
required to mobilize iron from the brain (Miyajima and Hosoi,
1993–2018; Mariani et al., 2004; Pelucchi et al., 2018). The
efficacy of phlebotomies appears even lower than iron chelation,
since CP deficiency likely impairs mobilization of tissue iron
stores notwithstanding the induction of marked erythropoietic
demand by blood removal. Indeed, failure to reduce liver iron
overload, as well as development of neurological symptoms,
have been occasionally reported in ACP patients treated with
phlebotomies (Hellman et al., 2000; Watanabe et al., 2018). In
few cases, iron chelation has been combined with fresh frozen
plasma (FFP) administration (aimed to restore CP levels), with
transient beneficial effects in a couple of studies (Yonekawa
et al., 1999; Poli et al., 2017). Other strategies are based on
preventing oxidative tissue damage by administration of vitamin
E or zinc sulfate (Pelucchi et al., 2018). The latter has been
associated to a dramatic neurological improvement in a patient
with extrapyramidal signs and cerebellar movement disorder
(Kuhn et al., 2007). Its effects on iron absorption, as well as
the good tolerability make this drug a feasible option, also
associated to iron chelation therapy (Donangelo et al., 2002).
Tetracyclines have in vitro iron-chelating properties and are
known to be able to cross the blood-brain barrier (Grenier
et al., 2000). Amelioration of neurological dysfunction has
been reported in a patient treated with minocycline (Hayashida
et al., 2016). Finally, the administration of human CP to
CP-knock-out mice was able to pass the blood-brain barrier,
rescued brain ferroxidase activity, reduced neuronal death and
brain iron deposits, and also ameliorated motor incoordination
(Zanardi et al., 2018). Whether or not the use of a recombinant
CP treatment could be successful in human ACP remains to
be demonstrated.
CONCLUDING REMARKS
Aceruloplasminemia is a rare proteiform disorder that can
be faced by different specialists at different times. A high
degree of suspicion is needed, and a proper early diagnosis
is critical. To this end, the biochemical triad of mild anemia
with low TSAT and high ferritin levels not due to any obvious
alternative explanation is likely the best clue. The disease should
be always suspected in any case of unexplained liver iron
overload, diabetes mellitus in young adults with no classical
risk factors, as well as in adult onset neurological dysfunctions
(behavioral changes, psychiatric disorders, extrapyramidal or
cerebellar signs) with MRI showing hypointensity in T2 FSE
and T2∗ sequences in dentate nucleus of cerebellum, basal
ganglia and thalamus. A better understanding of ACP molecular
pathophysiology is needed, possibly leading to novel treatments
in alternative to poorly effective current options. Considering
the rarity of ACP and the lack of uniformity in cases described,
a multicenter international registry should be instrumental
to improve knowledge about this highly invalidating iron
metabolism disorder.
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